Drug-maker Cipla posted profit after tax of Rs 268 crore for the three months ended March 31, 2013, down eight per cent from Rs 292 crore in the corresponding period last year.
The company’s Whole-time Director S. Radhakrishnan attributed the fall to the seasonal slowdown in the domestic branded generic drugs business, often the case in the fourth quarter, and to the timing of the overseas tender business.
The company’s gross revenues grew by close to five per cent, at Rs 1,982 crore in the quarter under review, compared to Rs 1,890 crore in the corresponding period last year.
Cipla ended the 2012-13 financial year with revenues of Rs 8,279 crore, compared to Rs 7,020 crore in the previous fiscal. Net profit for the year stood at Rs 1,544 crore, up from Rs 1,144 crore in 2011-12.